,headline,final_score,datetime
0,Bristol-Myers Squibb: Attractive Entry As New Products Sales Accelerate,86,2023-05-04 22:52:37
2,"Bristol-Myers EVP Vessey sells 50,385 common shares",86,2023-05-03 21:54:00
3,Bristol Myers Squibb Co. stock outperforms market on strong trading day,90,2023-05-03 20:42:00
5,Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy,57,2023-05-03 03:59:00
6,Bristol-Myers says EC grants approval for Breyanzi,86,2023-05-02 23:00:00
7,"Bristol Myers Squibb Co. stock falls Wednesday, underperforms market",90,2023-05-02 20:42:00
10,Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference,86,2023-05-02 03:59:00
12,Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors,90,2023-05-01 20:42:00
13,Barclays Maintains Bristol-Myers Squibb (BMY) Equal-Weight Recommendation,86,2023-05-01 09:04:15
14,"Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report",86,2023-05-01 05:32:00
16,Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate,57,2023-05-01 03:59:00
17,US FDA and EMA accept Bristol-Myers Squibb's submissions for Rebloyzl,86,2023-05-01 02:01:00
18,Bristol Myers Gets FDA Priority Review for Expanded Reblozyl Use >BMY,86,2023-05-01 00:20:00
19,"Bristol Myers, Merck anemia therapy undergoes U.S. and EU review for label expansion",86,2023-04-30 23:54:00
20,Bristol-Myers announces Reblozyl sBLA accepted for priority review,86,2023-04-30 23:09:00
21,"Immix says Bristol-Myers exercises option, enters license for TCR-T candidate",86,2023-04-30 23:06:00
22,Bristol-Myers reports `positive` results from TRANSCEND studies,86,2023-04-30 23:01:00
23,Bristol Myers (BMY) Gets a Hold from Barclays,86,2023-04-30 21:25:00
24,Bristol-Myers price target lowered to $65 from $66 at Barclays,86,2023-04-30 21:11:00
25,Bristol Myers Squibb Co. stock outperforms competitors on strong trading day,90,2023-04-30 20:42:00
26,"In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$8.0b market cap drop, institutional owners may be forced to take severe actions",90,2023-04-30 07:00:10
29,"Bristol Myers Squibb Co. stock falls Friday, underperforms market",90,2023-04-28 09:41:00
30,Credit Suisse Maintains Bristol-Myers Squibb (BMY) Neutral Recommendation,86,2023-04-28 08:43:47
31,Bristol-Myers Squibb Q1 Earnings: Is CEO Caforio's Sudden Departure A Concern?,86,2023-04-28 02:00:27
32,Bristol-Myers Squibb Q1 Earnings: Is CEO Caforio`s Sudden Departure A Concern?,86,2023-04-28 01:05:00
33,Bristol-Myers price target lowered to $72 from $78 at Credit Suisse,86,2023-04-28 00:06:00
34,"Bristol Myers Opdivo, Yervoy get EMA panel backing for skin cancer in adolescents",86,2023-04-27 22:27:00
35,Q1 2023 Bristol-Myers Squibb Co Earnings Call,90,2023-04-27 21:26:37
36,Morgan Stanley Sticks to Their Sell Rating for Bristol Myers (BMY),86,2023-04-27 21:25:00
37,"Bristol Myers, LianBio`s heart therapy Camzyos gets EMA panel nod",86,2023-04-27 20:49:00
38,Barclays Sticks to Their Hold Rating for Bristol Myers (BMY),86,2023-04-27 20:26:00
39,Goldman Sachs Keeps Their Buy Rating on Bristol Myers (BMY),86,2023-04-27 18:06:00
40,"Bristol Myers Squibb Posts Lower Q1 Sales As Revlimid Generic Erosion Bites, Chairman & CEO Giovanni Caforio To Step Down",86,2023-04-27 10:45:41
42,"Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales",86,2023-04-27 09:16:04
43,"Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics",86,2023-04-27 07:00:02
44,Bristol Myers looks to new CEO as competition from generic drugs heats up,86,2023-04-27 06:10:18
45,UPDATE 1-Bristol Myers looks to new CEO as competition from generic drugs heats up,86,2023-04-27 06:10:14
46,Bristol Myers Squibb (BMY) Surpasses Q1 Earnings Estimates,86,2023-04-27 05:15:12
47,Bristol-Myers Squibb Company 2023 Q1 - Results - Earnings Call Presentation,90,2023-04-27 04:20:19
48,Bristol-Myers Squibb Company (BMY) Q1 2023 Earnings Call Transcript,90,2023-04-27 04:19:04
49,Bristol Myers posts lower Q1 sales as Revlimid falls,86,2023-04-27 03:59:00
50,Bristol Myers Squibb Reports First Quarter Financial Results for 2023,86,2023-04-27 03:59:00
52,See Which Of The Latest 13F Filers Holds Bristol Myers Squibb,86,2023-04-27 01:40:00
53,Bristol-Myers Squibb revenue declines on Revlimid generic drug hit,86,2023-04-27 01:26:00
54,CEOs of Pioneer Natural Resources and Bristol-Myers Squibb to retire,86,2023-04-27 01:17:20
55,BMY Trends Lower on Mixed Q1,60,2023-04-27 00:58:00
56,Bristol Myers Q1 profit beats while revenue falls slightly short of estimates,86,2023-04-27 00:21:00
57,Bristol Myers stock dips as Q1 revenue falls amid generic impact on Revlimid,86,2023-04-27 00:17:00
58,Bristol Myers: Q1 Earnings Snapshot,86,2023-04-27 00:09:00
59,"Bristol-Myers Squibb Company  Non-GAAP EPS of $2.05 beats by $0.05, revenue of $11.3B misses by $290M",90,2023-04-26 23:37:00
60,"Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06",86,2023-04-26 23:00:00
61,"Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97",86,2023-04-26 22:59:00
63,Bristol Myers CEO Caforio to step down,86,2023-04-26 15:41:43
64,UPDATE 2-Bristol Myers CEO Caforio to step down,86,2023-04-26 15:41:40
65,CORRECTED-UPDATE 1-Bristol Myers CEO Caforio steps down,86,2023-04-26 14:48:44
66,Bristol-Myers CEO Giovanni Caforio to Step Down,86,2023-04-26 13:35:00
67,Bristol Myers Squibb Announces Leadership Transition Plan,86,2023-04-26 13:14:00
68,Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM),86,2023-04-26 11:42:00
71,Should You Buy Bristol Myers Squibb (BMY) Ahead of Earnings?,86,2023-04-26 05:46:12
72,Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production,86,2023-04-26 03:59:00
74,Will Bristol-Myers Squibb Q4 positive trend continue in Q1?,86,2023-04-26 03:01:00
75,"The Zacks Analyst Blog Highlights Bristol-Myers Squibb, Medtronic, Altria Group, Target and FedEx",86,2023-04-26 02:56:09
78,Bristol Myers to acquire viral vector manufacturing site in Illinois from Novartis,86,2023-04-25 23:58:00
80,Bristol-Myers adds new U.S. manufacturing facility for viral vector production,86,2023-04-25 23:04:00
81,"Bristol-Myers CEO Caforio to retire, will remain executive chairman",86,2023-04-25 20:15:00
82,Bristol-Myers reports positive CHMP opinion recommending approval for Camzyos,86,2023-04-25 18:44:00
83,"Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria Group",86,2023-04-25 10:47:05
84,"Bristol Myers Squibb Co. stock falls Tuesday, still outperforms market",90,2023-04-25 09:41:00
85,Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock,86,2023-04-25 06:40:01
90,"Bristol Myers Squibb Co. stock rises Monday, still underperforms market",90,2023-04-24 09:41:00
91,Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?,86,2023-04-24 08:57:03
93,We Think Bristol-Myers Squibb (NYSE:BMY) Can Stay On Top Of Its Debt,86,2023-04-24 04:00:22
96,"Bristol Myers Squibb Co. stock rises Friday, outperforms market",90,2023-04-21 09:41:00
98,B of A Securities Maintains Bristol-Myers Squibb (BMY) Buy Recommendation,86,2023-04-21 07:44:18
101,Bristol-Myers price target raised to $85 from $82 at BofA,86,2023-04-21 01:06:00
104,Bristol Myers Squibb Co. stock outperforms market despite losses on the day,90,2023-04-20 09:41:00
105,Bristol Myers Squibb (BMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release,86,2023-04-20 07:02:02
107,December 15th Options Now Available For Bristol Myers Squibb (BMY),86,2023-04-20 02:56:00
108,Evotec partner Tubulis signs deal with Bristol-Myers Squibb,86,2023-04-20 02:41:00
110,Bristol Myers inks up to $1B license deal with Tubulis to develop cancer drugs,86,2023-04-19 22:02:00
111,Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients,86,2023-04-19 22:00:00
112,Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know,86,2023-04-19 14:50:09
113,Bristol-Myers Squibb (NYSE:BMY) shareholders have earned a 9.7% CAGR over the last five years,86,2023-04-19 06:00:26
121,Bristol-Myers Squibb: A Recession-Resistant Route Forward,86,2023-04-18 10:00:41
122,Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day,90,2023-04-18 09:41:00
126,"Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expanded use",86,2023-04-17 21:09:00
127,"Bristol Myers (BMY), TSVT Application for Abecma Accepted",86,2023-04-17 10:13:05
135,"Bristol Myers, 2seventy: Earlier Abecma Use Advances With Three Regulators",86,2023-04-17 00:30:00
136,Bristol-Myers granted three applications for myeloma candidate Abecma,86,2023-04-16 23:03:00
138,Bristol-Myers` Juno get orphan designation for lisocabtagene maraleucel,86,2023-04-16 18:57:00
140,How Did Bristol-Myers Squibb Company's (NYSE:BMY) 20% ROE Fare Against The Industry?,90,2023-04-15 04:01:09
141,Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors,90,2023-04-14 09:41:00
144,"Bristol Myers Squibb Co. stock rises Thursday, still underperforms market",90,2023-04-13 09:41:00
147,"Bristol Myers Squibb Co. stock falls Tuesday, underperforms market",90,2023-04-11 09:41:00
148,Foundation Medicine to develop companion diagnostic for Bristol Myers` cancer drug repotrectinib,86,2023-04-11 03:26:00
150,Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development,86,2023-04-11 00:04:00
151,Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors,90,2023-04-10 09:41:00
152,Bristol-Myers Squibb Company (NYSE:BMY) insiders sold US$35m worth of stock suggesting impending weakness.,90,2023-04-10 06:00:22
153,GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market,86,2023-04-10 01:26:10
154,GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market,86,2023-04-10 00:28:00
158,Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?,86,2023-04-06 09:44:04
162,"Bristol Myers Squibb Co. stock rises Wednesday, outperforms market",90,2023-04-05 09:41:00
163,Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?,86,2023-04-05 09:10:04
164,Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57,86,2023-04-05 03:30:46
165,MRK vs. BMY: Which Pharmaceutical Stock is Better?,60,2023-04-05 01:19:00
167,"Ex-Dividend Reminder: Bristol Myers Squibb, UDR and Lincoln National",86,2023-04-04 02:24:00
168,Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know,86,2023-04-03 14:50:09
169,Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors despite daily gains,90,2023-04-03 09:41:00
170,Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion,86,2023-04-03 09:03:04
174,Here's What We Like About Bristol-Myers Squibb's (NYSE:BMY) Upcoming Dividend,86,2023-04-01 05:36:11
175,Unusual Put Option Trade in Bristol-Myers Squibb (BMY)  Worth $726.85K,86,2023-03-31 13:35:19
176,Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy,86,2023-03-31 05:07:00
177,Bristol Myers Gets CHMP Backing for Second-Line Breyanzi >BMY,86,2023-03-31 01:42:00
178,Bristol Myers` blood cancer drug Breyanzi gets EMA greenlight for earlier use,86,2023-03-31 01:03:00
180,Bristol-Myers announces CHMP opinion recommending approval for Breyanzi,86,2023-03-31 00:10:00
181,Unusual Call Option Trade in Bristol-Myers Squibb (BMY)  Worth $534.73K,86,2023-03-30 13:40:39
182,Bristol Myers' Flagship Opdivo Shows Long Term Durable Benefits In Lung Cancer Patients,86,2023-03-30 11:18:04
183,Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst institutional investors who own 77%,90,2023-03-30 07:00:33
